Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam, Collaborators Report on RNAi Enhancement of Dendritic Cancer Cell Vaccine


Alnylam Pharmaceuticals last week published preclinical data describing the development of a dendritic cell cancer vaccine enhanced with RNAi.

According to the company, its researchers and collaborators from Radboud University Nijmegen Medical Centre designed siRNAs toward PD-L1 and PD-L2, which are “key co-inhibitory proteins expressed on antigen-presenting cells that strongly limit activation of T-cells needed for a potent immune response to the tumor.”

“Lipid nanoparticle-formulated siRNA targeting PD-L1 and PD-L2 mediated efficient and specific silencing of PD-L1 and PD-L2 expression on human monocyte-derived [dendritic cells] isolated from healthy donors,” Alnylam said in a statement. “Ex vivo treatment with siRNA was well tolerated by the isolated [cells], with no measurable effect on phenotype or migratory capacity.”

Dendritic cells treated with the siRNAs were loaded with mRNA encoding minor histocompatibility antigen to allow “long-lasting presentation of antigenic peptides expressed by malignant cells,” it added. “The resulting PD-L silenced, MiHA-expressing DCs were shown to have a significantly enhanced ability to stimulate antigen-specific CD8+ T cell responses in cells from transplanted cancer patients ex vivo.”

The findings appeared online last week in Cancer Immunology Immunotherapy.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.